CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech which has been effective diligently but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.
In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.
CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is actually an open question.
While CYDY is actually dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.
I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good To Be True?”, set away the following prediction:
Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire employment interview which I came away with a bad opinion of the business.
Irony of irony, my bad impression of the business has grown steadily, however, the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.
What manner of stock is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.
CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back during 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and also associated intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) as well as the first new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales upon commercialization.
Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.
Rather than having a pipeline with numerous therapies and multiple indications, it’s this individual therapy in addition to a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.
Its opening banner on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations in addition to multiple publications.
Might all of it be smoke cigarettes and mirrors? That is a question I have been asking myself through the really beginning of my interest in this particular organization. Judging by way of the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.
CytoDyn is a classic battleground, or possibly some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short-mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News